Lack Of Funding Has "Hobbled" FDA Postmarketing Drug Safety Work – IoM
This article was originally published in The Pink Sheet Daily
Executive Summary
Substantially increased resources are needed to improve FDA's drug safety activities and implement IoM recommendations, report says.